Physician
Oncology
Dr. Stephen P. Creekmore, MD
|
|
Give Review
Dr. Stephen P. Creekmore practices Oncology. He went to medical school at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a one of the best medicals schools. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care Stephen Creekmore is also a published doctor. He has 45 paper published. The most recent paper is: Alterations in T cell receptor and signal transduction molecules in melanoma patients.
Publications
- Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
- Purification of clinical-grade disulfide stabilized antibody fragment variable-Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli.
- Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.
- IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T-effector memory population in peripheral blood.
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
- Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.
- Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
- Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
- A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.
- Effects of interleukin-2 immunotherapy on renal function.
- Stopping a silent killer. Preventing heart disease in women.
- Effect of level of lung injury on HR, MAP and SaO2 changes during suctioning.
- A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), C...
- IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.
- The measurement of systolic time intervals by echocardiography.
- Carboplatin for advanced colorectal carcinoma: a phase II study.
- The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.
- In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
- Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
- Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.
- Hypothyroidism after interleukin-2 therapy.
- A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
- Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.
- Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
- Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
- Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.
- Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial.
- Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
- Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
- Alterations in T cell receptor and signal transduction molecules in melanoma patients.
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
- Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in c...
- T cell activation via the disialoganglioside GD3: analysis of signal transduction.
- Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
- The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
- Dose-related immunologic effects of levamisole in patients with cancer.
- Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3)
- Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
- Comparison of methods of recording and analysis of Doppler blood velocity signals in normal subjects.
- A preliminary model of double-minute-mediated gene amplification.
- Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and light.
- Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
- MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and sta...
Schools
University of California At San Francisco
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Southern California - LAC+USC Medical Center -
University of California San Francisco School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Paul G. Rausch, MD
 This Doctor is OpenDoctor Recommended.
|